Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) Comparison with companies in other sectors?

Zylox-Tonbridge Medical Technology Co., Ltd. has a share price of 312.02M. You can analyze Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) competitors across different market sectors through stock heatmaps.

What are 2190.HK's NET and operating margins?

Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) operating margin is around 0.00, and net profit margin is approximately 0.13 as of the latest reports.

In what way does 2190.HK's earnings per share (EPS) trend reflect its financial momentum?

Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) EPS is 0.33 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Zylox-Tonbridge Medical Technology Co., Ltd. is 67.94, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Zylox-Tonbridge Medical Technology Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Zylox-Tonbridge Medical Technology Co., Ltd. like P/E which is 67.15, P/B which is 2.17, and PEG which is 0.25. Compare them with sector averages to evaluate if the stock is priced fairly.

Zylox-Tonbridge Medical Technology Co., Ltd.

2190.HK•HKSE

Healthcare

Medical - Devices

HK$22.70

HK$0.20(0.89%)

Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.33

P/E Ratio

67.94

ROE

0.03%

Net Margin

0.13%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.00B

Shares OutstandingTotal number of shares issued

$312.02M

Book Value/ShareNet worth per share

$9.45

Revenue/ShareAnnual revenue per share

$2.38

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.33

Net MarginNet income as percentage of revenue

12.81%

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

3.23%

ROAReturn on total assets

2.90%

ROCEReturn on capital employed

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.05

Cash/ShareCash and equivalents per share

$3.91

FCF YieldFree cash flow as percentage of market cap

-0.28%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.10

Dividend YieldAnnual dividend as percentage of stock price

0.49%

Financial Ratios Analysis data is not available for 2190.HKFinancial Ratios Analysis details for 2190.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2190.HKSector Benchmarking details for 2190.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Zylox-Tonbridge Medical Technology Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Zylox-Tonbridge Medical Technology Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Zylox-Tonbridge Medical Technology Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Zylox-Tonbridge Medical Technology Co., Ltd.

For Zylox-Tonbridge Medical Technology Co., Ltd., essential financial indicators include EPS 0.33, PE 67.94, and ROE 0.03. These key ratios reveal insights into Zylox-Tonbridge Medical Technology Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Zylox-Tonbridge Medical Technology Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Zylox-Tonbridge Medical Technology Co., Ltd.

Metrics like Net Margin 12.81% and ROA 2.90% shed light on how well Zylox-Tonbridge Medical Technology Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Zylox-Tonbridge Medical Technology Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Zylox-Tonbridge Medical Technology Co., Ltd.

Using ratios such as P/B Ratio 2.17 and PEG Ratio 0.25, investors can assess whether Zylox-Tonbridge Medical Technology Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Zylox-Tonbridge Medical Technology Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Zylox-Tonbridge Medical Technology Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $-0.05, provide a snapshot of Zylox-Tonbridge Medical Technology Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Zylox-Tonbridge Medical Technology Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Zylox-Tonbridge Medical Technology Co., Ltd.

Investing in Zylox-Tonbridge Medical Technology Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Zylox-Tonbridge Medical Technology Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;